Last reviewed · How we verify
HSK7653 tablets
At a glance
| Generic name | HSK7653 tablets |
|---|---|
| Also known as | HSK7653 |
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes (NA)
- HSK7653 in Chinese Patients with Impaired Glucose Tolerance (PHASE2)
- A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients (PHASE2)
- Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM (PHASE2)
- Single Escalating Dose Study Of HSK7653 In Healthy Subjects (PHASE1)
- A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment (PHASE1)
- HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (PHASE3)
- HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK7653 tablets CI brief — competitive landscape report
- HSK7653 tablets updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI